Skip to main content

Table 2 Plasma cytokines portraits of primary ITP patients (pg/ml)

From: Distinct alterations of CD68+CD163+ M2-like macrophages and myeloid-derived suppressor cells in newly diagnosed primary immune thrombocytopenia with or without CR after high-dose dexamethasone treatment

  Health control (n = 10) Primary ITP (n = 23)
Eotaxin-1/CCL11 220.40 (195.40–220.40) 154.5 (106.80–189.10)***
Eotaxin-2 (×103) 1.17 (0.84–2.20) 0.92 (0.49–1.41)
G-CSF 825.40 (562.20–855.90) 76.70 (37.00–175.90)***
GM-CSF 80.05 (66.35–97.28) 11.00 (8.00–16.90)***
I-309 83.70 (68.45–134.50) 33.70 (19.60–55.70)***
ICAM-1 (×103) 39.40 (16.75–43.33) 21.87 (6.46–45.08)
IFNγ (×103) 0.79 (0.71–0.94) 0.16 (0.12–0.20)**
IL-1α (×103) 1.16 (0.94–1.33) 0.20 (0.11–0.45)***
IL-1β 65.75 (59.90–79.70) 37.80 (24.10–47.50)***
IL-1ra (×103) 1.28 (1.01–1.63) 0.35 (0.26–0.41)***
IL-2 264.90 (187.80–343.20) 44.90 (33.10–71.60)***
IL-4 415.40 (340.80–504.10) 110.5 (54.7–164.0)***
IL-5 185.40 (158.00–243.40) 42.10 (32.70–51.60)***
IL-6 83.90 (59.03–101.40) 16.50 (7.90–26.80)***
IL-6R (×103) 17.90 (17.86–18.78) 17.80 (17.80–18.90)
IL-7 130.30 (96.93–147.60) 26.20 (22.10–34.60)***
IL-8 99.40 (75.40–121.80) 11.90 (7.70–19.30)***
IL-10 94.45 (63.40–192.20) 17.10 (11.10–23.40)***
IL-11 (×103) 1.43 (1.07–1.93) 0.41 (0.24–0.53)***
IL-12p40 15.85 (12.20–26.78) 13.50 (4.50–18.10)
IL-12p70 41.85 (28.08–55.05) 7.30 (4.60–9.80)***
IL-13 37.80 (26.48–46.33) 10.10 (6.10–12.90)***
IL-15 57.50 (35.35–71.68) 27.60 (12.20–36.90)*
IL-16 124.40 (75.65–171.50) 62.30 (31.80–106.60)*
IL-17A 29.95 (14.50–41.38) 4.00 (1.80–6.80)***
MCP-1 (×103) 0.30 (0.27–0.35) 0.16 (0.12–0.30)**
M-CSF 20.45 (16.28–28.30) 8.20 (4.20–14.00)**
CXCL9/MIG 52.55 (39.88–67.83) 44.60 (25.80–55.00)
MIP-1α/CCL3 25.10 (20.45–30.30) 17.30 (10.60–24.30)*
MIP-1β 97.05 (88.08–140.40) 85.50 (63.50–155.00)
MIP-1d (×103) 1.31 (0.88–2.95) 1.80 (0.95–2.94)
PDGF-BB (×103) 5.36 (3.87–6.72) 0.70 (0.34–1.82)***
RANTES (×103) 14.62 (13.92–15.71) 8.90 (4.08–14.59)**
TIMP-1 (×103) 8.21 (7.00–10.29) 16.13 (11.99–19.03)***
TIMP-2 (×103) 20.46 (13.93–32.76) 11.92 (7.81–14.82)**
TNFα (×103) 1.06 (0.71–1.80) 0.24 (0.15–0.37)***
TNFβ (×103) 0.90 (0.70–1.65) 0.30 (0.21–0.38)***
TNFRI (×103) 5.21 (4.11–5.93) 7.02 (5.40–13.51)*
TNFRII (×104) 1.80 (1.53–2.01) 2.12 (1.82–3.17)*
  1. Data are presented as median (interquartile range)
  2. CCL11 CeC motif chemokine 11, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte–macrophage colony-stimulating factor, ICAM-1 intercellular adhesion molecule-1, IFNγ interferon-gamma, IL interleukin, MCP-1 monocyte chemoattractant protein-1, M-CSF macrophage colony-stimulating factor, CXCL9 CXC ligand 9, MIP macrophage-inflammatory protein, PDGF-BB platelet-derived growth factor BB, RANTES regulated on activation normal T expressed and secreted chemokines, TIMP tissue inhibitor of metalloproteinases, TNF tumor necrosis factor, TNFR tumor necrosis factor receptor
  3. * p < 0.05; ** p < 0.01; *** p < 0.001, ITP(n = 23) compared with HC(n = 10)